<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952054</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0007</org_study_id>
    <secondary_id>NCI-2014-01273</secondary_id>
    <nct_id>NCT01952054</nct_id>
  </id_info>
  <brief_title>Denosumab for Breast Cancer With Bone Mets</brief_title>
  <official_title>Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if denosumab in combination with a
      hormonal drug can help lower the number of circulating tumor cells (CTCs) in patients with
      breast cancer that has spread to the bone. The safety of this combination will also be
      studied.

      This is an investigational study. Denosumab is FDA approved and commercially available to
      prevent bone-related events caused by breast cancer that has spread to the bone. Using
      denosumab to lower CTCs in patients with breast cancer that has spread to the bone is
      investigational.

      You may have the option of continuing denosumab after the study ends.

      Up to 35 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will receive denosumab
      through a needle under your skin on Day 1 of each 28-day study cycle.

      Starting on Day 1 of week 4, you will also begin taking a hormonal drug. The study doctor
      will choose the hormonal drug you receive based on your previous hormonal therapy for breast
      cancer. The study doctor will give you instructions for taking your hormonal drug.

      Study Visits:

      On Day 1 of week 4:

        -  You will have a physical exam

        -  Blood (about 3 tablespoons) will be drawn for routine tests

        -  Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.

        -  Urine will be collected to test for a biomarker that is used to measure the rate of bone
           breakdown.

        -  If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an
           MRI to check the status of the disease.

      On Day 1 of Cycle 2 and Cycle 3, blood (about 1 teaspoon) will be drawn for routine tests.

      Length of Study:

      You may receive the denosumab and hormonal therapy combination for up to 13 weeks. You will
      be taken off study if the disease gets worse or intolerable side effects occur.

      End of Study Visit:

      After your last dose of the study drug, the following tests and procedures will be performed:

        -  You will have a physical exam.

        -  Blood (about 3 tablespoons) will be drawn for routine tests.

        -  Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.

        -  Urine will be collected to test for a biomarker that is used to measure the rate of bone
           breakdown.

        -  If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an
           MRI to check the status of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 9, 2015</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) Among Breast Cancer Patients With Bone Metastases.</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The difference in number of CTCs in 7.5 ml whole blood from baseline to week4. CTC reduction from baseline to week4 is statistically analyzed using the two-sided paired t-test with the significance level of 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Changes of Epithelial-mesenchymal Transition (EMT) in CTCs</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The change in Her2, Muc-1, GA733-2 (EpCAM), Twist, Akt, PI3K and ALDH-1 in CTCs after 1 st cycle of treatment with denosumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Changes in Urine N-telopeptide Level</measure>
    <time_frame>Baseline up to week 13</time_frame>
    <description>The collection urine is performed at baseline, at week4 and the end of 3rd cycle (week13) to evaluate the level of N-telopeptide.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>120 mg subcutaneously on Day 1 of every 28 day cycle.</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>AMG 162</other_name>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients have histological confirmation of breast carcinoma.

          2. Patients have progressive metastatic disease with predominantly bone metastasis with 1
             or more lesions and at least 1 bone lesion has pathological confirmation, have not
             been treated or have been treated with any prior therapies (including bisphosphonate
             treatment and/or radiation therapy). Patients can have soft tissue involvement (Lymph
             node and skin) and/or metastatic lesions at major organ sites (i.e. lung, liver, etc).

          3. Patients have positive ER expression in the primary tumor site by IHC (defined as
             &gt;/=10%) (PR status is not required)

          4. Adequate hematologic function: 1)Absolute neutrophil count (ANC) &gt;/= 1.0 x 10^9/L, 2)
             Platelet count &gt;/= 50 x 10^9/L, 3) Hemoglobin &gt;/= 9.0 g/dL

          5. Adequate cardiac function (LVEF &gt;/= 45%) if patient has known cardiac dysfunction
             history

          6. Adequate Renal function: Calculated creatinine clearance &gt;30 ml/min

          7. Adequate Hepatic function: 1) Aspartate aminotransferase (AST) &lt;/= 2.5 x ULN; 2)
             Alanine aminotransferase (ALT) &lt;/= 2.5 x ULN; 3) Alkaline phosphatase (Alp) &lt;/= 2.5 x
             ULN; 4) Total bilirubin &lt;/= 2.0 x ULN

          8. Serum calcium or albumin-adjusted serum calcium &gt;/=2.0mmol/L (8.0mg/dL) and &lt;/= 2.9
             mmol/L (11.5mg/dL)

          9. Patients have ability and willingness to sign written informed consent.

         10. Patients are 18 years of age or older.

         11. Female patients of childbearing potential (A female not free from menses &gt; 2 years or
             not surgically sterilized) must be willing to use highly effective contraception to
             prevent pregnancy or agree to abstain from heterosexual activity throughout the study.
             Highly effective contraception, defined as male condom with spermicide, diaphragm with
             spermicide, intra-uterine device. Highly effective contraception must be used by both
             sexes during the study and must be continued for 5 months after the last dose of
             denosumab.

         12. Female patients of childbearing potential must have negative serum pregnancy test &lt;/=
             21 days prior to starting study treatment.

         13. Patients have CTC &gt;/=3.

        Exclusion Criteria:

          1. Patients have known sensitivity to any of the products to be administered during the
             study (e.g., mammalian derived products, calcium, or vitamin D).

          2. Patients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy,
             radiation therapy and biological therapy) while taking study medication. However,
             patients receiving CDK4/6 inhibitor or mTOR inhibitor as a standard of care while on
             study is permitted.

          3. Patients with metastatic sites that requires chemotherapy.

          4. Patients with active infection and requiring IV or oral antibiotics.

          5. Patients with concurrent disease or condition that would make them inappropriate for
             study participation, or any serious medical disorder that would interfere with
             patients' safety.

          6. Patients have HER2-positive breast carcinoma (IHC staining more than 3+ or HER2 gene
             amplification by FISH)

          7. Patient is pregnant or breast feeding, or planning to become pregnant within 5 months
             after the end of treatment.

          8. Patient is of child bearing potential and is not willing to use, in combination with
             her partner, two highly effective methods of contraception or abstinence during
             treatment and for 5 months after the end of treatment.

          9. Male patients.

         10. Patients have prior history or current evidence of osteonecrosis/osteomyelitis of the
             jaw.

         11. Patients have active dental or jaw condition which requires oral surgery, including
             tooth extraction.

         12. Patients have non healed dental/oral surgery, including tooth extraction.

         13. Patients planned invasive dental procedures.

         14. Patients experiencing a visceral crisis including severe organ dysfunction as assessed
             by &gt; Gr 2 symptomatic toxicities, laboratory studies, and/ or rapid progression of
             disease originating from visceral metastasis.

         15. Patients that have received the study medication (Xgeva/Prolia).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <results_first_submitted>October 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast carcinoma</keyword>
  <keyword>Bone metastasis</keyword>
  <keyword>Cancer that has spread to the bone</keyword>
  <keyword>Denosumab</keyword>
  <keyword>AMG 162</keyword>
  <keyword>Prolia</keyword>
  <keyword>Hormonal agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01952054/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 8, 2015 to Apr 4, 2017. All recruitment performed at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>One participant was ineligible due to screen failure</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab</title>
          <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab</title>
          <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) Among Breast Cancer Patients With Bone Metastases.</title>
        <description>The difference in number of CTCs in 7.5 ml whole blood from baseline to week4. CTC reduction from baseline to week4 is statistically analyzed using the two-sided paired t-test with the significance level of 0.05.</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>The primary objective could not be met due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) Among Breast Cancer Patients With Bone Metastases.</title>
          <description>The difference in number of CTCs in 7.5 ml whole blood from baseline to week4. CTC reduction from baseline to week4 is statistically analyzed using the two-sided paired t-test with the significance level of 0.05.</description>
          <population>The primary objective could not be met due to technical issues.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes of Epithelial-mesenchymal Transition (EMT) in CTCs</title>
        <description>The change in Her2, Muc-1, GA733-2 (EpCAM), Twist, Akt, PI3K and ALDH-1 in CTCs after 1 st cycle of treatment with denosumab.</description>
        <time_frame>Baseline, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes of Epithelial-mesenchymal Transition (EMT) in CTCs</title>
          <description>The change in Her2, Muc-1, GA733-2 (EpCAM), Twist, Akt, PI3K and ALDH-1 in CTCs after 1 st cycle of treatment with denosumab.</description>
          <units>ng/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HER 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".003" spread=".032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muc-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".065" spread=".062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GA733-2 (EpCAM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.372" spread=".750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Twist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".018" spread=".045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Akt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".028" spread=".077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALDH-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".328" spread=".808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Changes in Urine N-telopeptide Level</title>
        <description>The collection urine is performed at baseline, at week4 and the end of 3rd cycle (week13) to evaluate the level of N-telopeptide.</description>
        <time_frame>Baseline up to week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
          </group>
        </group_list>
        <measure>
          <title>The Changes in Urine N-telopeptide Level</title>
          <description>The collection urine is performed at baseline, at week4 and the end of 3rd cycle (week13) to evaluate the level of N-telopeptide.</description>
          <units>nmol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion 13 weeks</time_frame>
      <desc>A serious adverse event is any adverse drug experience occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity and a congenital anomaly/birth detect. One participant was ineligible due to screen failure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Denosumab</title>
          <description>Subcutaneous administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, also receive a hormonal agent chosen by physician.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 4.0.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders-other specify-red/burning, tearing eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hip pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ueno,Naoto,M.D., PH.D. / Breast Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-2817</phone>
      <email>nueno@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

